- In May 2024, Insmed Incorporated announced positive results from the Phase III ASPEN trial evaluating Brensocatib, an oral DPP1 inhibitor, for the treatment of non-cystic fibrosis bronchiectasis. The trial demonstrated a statistically significant reduction in the annualized rate of pulmonary exacerbations. This advancement marks a major milestone, positioning Brensocatib as a potential first-in-class treatment for bronchiectasis
- In April 2024, Armata Pharmaceuticals advanced its investigational phage therapy candidate AP-PA02 into a Phase Ib/IIa clinical trial for patients with bronchiectasis caused by Pseudomonas aeruginosa. This bacteriophage-based treatment represents a novel approach to managing chronic infections in bronchiectasis patients who are resistant to conventional antibiotics
- In March 2024, researchers at the European Respiratory Society (ERS) reported progress on the EMBARC registry, a major pan-European initiative collecting longitudinal data on non-CF bronchiectasis patients. The real-world data from over 17,000 patients is helping shape treatment protocols and identify unmet clinical needs
- In February 2024, Zambon S.p.A. announced the expansion of its Colistimethate sodium inhalation solution (Promixin) availability in new European markets for managing chronic P. aeruginosa infections in bronchiectasis. This step enhances access to targeted inhaled antibiotic therapy for patients with limited treatment options
- In January 2024, Aradigm Corporation, in collaboration with regulatory authorities, reinitiated its strategy to bring Lipoquin and Pulmaquin—liposomal ciprofloxacin formulations—back into clinical development for bronchiectasis, following a previous regulatory setback. These long-acting inhaled antibiotics have potential to improve treatment adherence and reduce exacerbations
